Tempus AI (TEM) Stock Slides Despite FDA Greenlight for Cancer Diagnostic Platform

Tempus AI (TEM) stock declined 1.66% despite FDA authorization for its xT CDx tumor-only cancer test, marking a significant oncology diagnostic milestone.

The post Tempus AI (TEM) Stock Slides Despite FDA Greenlight for Cancer Diagnostic Platform appeared first on Blockonomi.